A condition affecting roughly 10–15% of reproductive-age women worldwide has long carried a name that poorly matched its biology — and that mismatch has quietly contributed to missed diagnoses, stigma, and inadequate treatment. The proposed renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), published in JAMA, represents a formal effort to realign nomenclature with decades of accumulated science.
The original name, coined in the 1930s, emphasized ovarian cysts visible on ultrasound — a feature now understood to be neither universal nor definitionally necessary. The new designation, PMOS, shifts emphasis toward the condition's more clinically meaningful characteristics: dysregulation across multiple endocrine axes (including androgen excess, insulin resistance, and hypothalamic-pituitary dysfunction) alongside its core metabolic dimensions such as elevated cardiometabolic risk, type 2 diabetes predisposition, and chronic low-grade inflammation. The name change was developed through an international consensus process involving endocrinologists, gynecologists, and patient advocates, signaling broad institutional backing rather than a fringe proposal.
Renaming a disease rarely feels urgent, but diagnostic labels carry real clinical weight. The ovarian-cyst framing led generations of clinicians to rule out the diagnosis when cysts were absent on imaging, leaving a significant subset of patients — particularly lean women with predominantly metabolic presentations — undiagnosed for years. The shift to PMOS could prompt updated diagnostic criteria that prioritize hormonal and metabolic markers over morphology. From a longevity standpoint, earlier identification matters considerably: untreated metabolic dysfunction in PMOS is associated with elevated lifetime risk for type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and adverse pregnancy outcomes. This reclassification is best understood as confirmatory of existing science rather than paradigm-shifting, but its practical downstream effects on screening protocols, insurance coding, and patient self-advocacy could be meaningfully positive over the coming decade.